TMIGD2 as a potential therapeutic target in glioma patients

INTRODUCTION: Among all types of central nervous system cancers, glioma remains the most frequent primary brain tumor in adults. Despite significant advances in immunomodulatory therapies, notably immune checkpoint inhibitors, their effectiveness remains constrained due to glioma resistance. The dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulhen, Chaimae, AIT SSI, Saadia, Benthami, Hamza, Razzouki, Ibtissam, Lakhdar, Abdelhakim, Karkouri, Mehdi, Badou, Abdallah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227580/
https://www.ncbi.nlm.nih.gov/pubmed/37261362
http://dx.doi.org/10.3389/fimmu.2023.1173518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227580/
https://www.ncbi.nlm.nih.gov/pubmed/37261362
http://dx.doi.org/10.3389/fimmu.2023.1173518

Ejemplares similares